The Long Wait for Long-acting HIV Prevention and Treatment Formulations

20 August 2024

This commentary from The Lancet HIV calls on WHO, financial donors, manufacturers, and governments to take coordinated action to make long-acting HIV prevention and treatment available at scale in lower and middle income countries.

Featured Resources

Spreadsheet

2024 Q2 Global PrEP Tracker

AVAC’s Global PrEP Tracker offers two views on PrEP uptake around the world. Visit data.prepwatch.org for a dynamic map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs. For insights on the full scope of PrEP use around the world, the PrEP Tracker as a spreadsheet offers…

Document

PURPOSE 1 Summary

This factsheet provides a summary of the PURPOSE 1 phase III clinical trial of lenacapavir for PrEP and F/TAF for cisgender women taking place in South Africa and Uganda.

External Link

Client Experiences with “Dynamic Choice Prevention,” a Model for Flexible Patient-centred HIV Prevention Delivery in Rural Eastern Africa

This article from Journal of the International AIDS Society discusses client experiences of a dynamic choice model for HIV prevention piloted in Kenya and Uganda under the SEARCH study, where clients were supported to select HIV prevention method, testing mode, and service delivery channel from a range of options.

Document

Coordinating Implementation Science for CAB for PrEP: HIV Testing

This document summarises key takeaways from a June 2024 BioPIC Think Tank to review and discuss emerging issues around cabotegravir (CAB) for PrEP implementation and HIV testing algorithms.

Document

Pre-Exposure Prophylaxis and Adolescent Girls and Young Women in Eastern and Southern Africa: The latest insights

Eastern and southern Africa (ESA) is the world’s most heavily HIV-impacted region, with adolescent girls and young women (AGYW) disproportionately affected. To support the scale-up of PrEP amongst AGYW in ESA, in September 2021 UNICEF and partners released the implementation brief “Improving the Quality of Pre-Exposure Prophylaxis Implementation for Adolescent Girls and Young Women in…

Document

CAB PrEP Introduction Supply Chain Considerations – Kenya 2023

This document summarizes considerations for the integration of CAB PrEP within Kenya’s supply chain system based on interview with key national and subnational stakeholders.

Presentation

Leading the Way: Early learnings from CAB for PrEP introduction in Zambia and Zimbabwe

Programmatic rollout of long-acting injectable cabotegravir (CAB for PrEP) has launched in Zambia and Zimbabwe! Recommended by the World Health Organization as a safe and effective HIV prevention method in 2022, these two countries are now the first in Africa to incorporate this new, long-awaited PrEP product into their national HIV prevention programs. In the…

Document

The Lens on LEN

In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention was safe and highly effective against HIV. The product is being tested among 5,300 HIV-negative cisgender women ages 16-25 in Uganda and South…

Spreadsheet

Access Workbook for Cabotegravir for PrEP and Dapivirine Vaginal Ring

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP and the dapivirine vaginal ring (DVR) for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit product pricing, and information…

Presentation

Generic CAB for PrEP Development and Access

This presentation from Medicines Patent Pool explains the process of licensing, developing, and manufacturing generic cabotegravir (CAB) for PrEP, including expected timelines for generic CAB for PrEP availability.